Published in Horm Res on January 01, 1992
[Hyperplasia and tumors of the parathyroid glands]. Pathologe (2003) 0.75
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (2002) 6.12
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis (2006) 2.72
Ankylosing spondylitis: an overview. Ann Rheum Dis (2002) 2.71
Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis (2011) 2.67
Positioning of total knee arthroplasty with and without navigation support. A prospective, randomised study. J Bone Joint Surg Br (2003) 2.61
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum (2003) 2.20
Clinical studies of multiple endocrine neoplasia type 1 (MEN1) QJM (1996) 1.93
Molecular evidence for tuberculosis in an ancient Egyptian mummy. Lancet (1997) 1.91
Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) (2005) 1.82
Importance of psychological well being and disease activity in termination of an initial DMARD therapy. J Rheumatol (1997) 1.77
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum (2008) 1.66
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis (2004) 1.53
HLA-DRB1 genes, rheumatoid factor, and elevated C-reactive protein: independent risk factors of radiographic progression in early rheumatoid arthritis. Berlin Collaborating Rheumatological Study Group. J Rheumatol (2000) 1.49
Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis (2008) 1.39
Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis (2009) 1.30
Loss of physical independence in rheumatoid arthritis: interview data from a representative sample of patients in rheumatologic care. Arthritis Care Res (2000) 1.29
[Diagnostic spectrum, treatment indication and symptom duration in initial referrals to the rheumatologist]. Z Rheumatol (2010) 1.28
[Burden of illness. First routine report on socio-medical consequences of inflammatory rheumatic disease in Germany]. Z Rheumatol (2008) 1.26
Ancient Egyptian prosthesis of the big toe. Lancet (2001) 1.18
Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. J Rheumatol (2000) 1.14
Detection of leprosy in ancient human skeletal remains by molecular identification of Mycobacterium leprae. Am J Clin Pathol (2000) 1.11
Morning stiffness and its influence on early retirement in patients with recent onset rheumatoid arthritis. Rheumatology (Oxford) (2008) 1.10
Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial. Arthritis Rheum (1996) 1.09
Burden and cost of illness in patients with juvenile idiopathic arthritis. Ann Rheum Dis (2004) 1.07
The economic burden of juvenile idiopathic arthritis-results from the German paediatric rheumatologic database. Clin Exp Rheumatol (2009) 1.02
Anthropological and palaeopathological analysis of the human remains from three "Tombs of the Nobles" of the necropolis of Thebes-west, upper Egypt. Anthropol Anz (2000) 0.98
Atopic disorders in ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis (2002) 0.98
[Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany]. Z Rheumatol (2003) 0.96
[Macroscopic and endoscopic examinations of the head and neck region in ancient Egyptian mummies]. HNO (2004) 0.95
PCR-induced sequence alterations hamper the typing of prehistoric bone samples for diagnostic achondroplasia mutations. Mol Biol Evol (2004) 0.94
Incidence and prevalence of juvenile chronic arthritis in East Berlin 1980-88. J Rheumatol (1998) 0.93
Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. Ann Rheum Dis (2004) 0.91
Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group. Rheumatology (Oxford) (2008) 0.90
Tumour necrosis factor receptor associated periodic syndrome (TRAPS) with central nervous system involvement. Ann Rheum Dis (2004) 0.90
Accidental poisoning in childhood from the epidemiological viewpoint-An analysis of 323 cases of poisoning in children under eight years of age-. Vet Hum Toxicol (1981) 0.90
[Routine report on the medical rehabilitation of patients with musculoskeletal diseases]. Z Rheumatol (2005) 0.89
Molecular evidence for different stages of tuberculosis in ancient bone samples from Hungary. Am J Phys Anthropol (2000) 0.87
[Prophylaxis and treatment of osteoporosis in patients with rheumatoid arthritis (ORA study)]. Z Rheumatol (2011) 0.86
[Comorbidity in rheumatoid arthritis of early onset. Effects on outcome parameters]. Z Rheumatol (2006) 0.86
[Paleopathology of ancient Egyptian mummies and skeletons. Investigations on the occurrence and frequency of specific diseases during various time periods in the necropolis of Thebes-West]. Pathologe (2002) 0.85
Major role of dihydropyridine-sensitive Ca2+ channels in Ca(2+)-induced calcitonin secretion. Am J Physiol (1993) 0.84
[Epidemiology of primary Sjörgren's syndrome]. Z Rheumatol (2010) 0.84
Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Rheumatology (Oxford) (2006) 0.84
[Epidemiological and socio-psychological aspects of accidents in childhood (author's transl)]. Monatsschr Kinderheilkd (1980) 0.83
Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis. Ann Rheum Dis (2008) 0.82
[Diagnosis and treatment of osteoporosis and rheumatoid arthritis in accordance with German guidelines. Results of a survey of patients, primary care physicians and rheumatologists]. Z Rheumatol (2011) 0.81
[Transition clinic--it is not always a simple segue in rheumatology for adults]. Z Rheumatol (2005) 0.81
Down-regulation of calcitonin receptors in T47D cells by internalization of calcitonin-receptor complexes. Mol Cell Endocrinol (1988) 0.80
Kinematic analysis and position/force control of the Anthrobot dextrous hand. IEEE Trans Syst Man Cybern B Cybern (1997) 0.79
Inhibition of Ca(2+)-induced calcitonin secretion by somatostatin: roles of voltage dependent Ca2+ channels and G-proteins. Cell Signal (1992) 0.78
[Biologics register JuMBO. Long-term safety of biologic therapy of juvenile idiopathic arthritis]. Z Rheumatol (2013) 0.78
[Help status and help prospects of severely handicapped patients with rheumatoid arthritis]. Z Rheumatol (2001) 0.78
[Prescription of glucocorticoids by rheumatologists in patients with rheumatoid arthritis in Germany]. Z Rheumatol (2005) 0.77
Measurement of free cytosolic calcium in single cells: method and application. Methods Find Exp Clin Pharmacol (1992) 0.77
Halophilic bacteria are colonizing the exhibition areas of the Capuchin Catacombs in Palermo, Italy. Extremophiles (2014) 0.77
[Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany]. Z Rheumatol (2004) 0.76
[Outcome measurement in musculoskeletal diseases: recommendation for a core set of scales for use in rehabilitation]. Z Rheumatol (2001) 0.76
[Methodologic aspects of public health economy]. Z Rheumatol (2004) 0.75
[Epidemiology of rheumatic diseases in the German Federal Republic-- current state and perspectives]. Z Rheumatol (1992) 0.75
[Out-of-pocket medical spending for care in patients with recent onset rheumatoid arthritis]. Z Rheumatol (2004) 0.75
[Accidental poisonings in children under eight years of age: epidemiology--social risks (author's transl)]. Przegl Lek (1981) 0.75
[New findings regarding an "ancient illness"]. MMW Fortschr Med (2000) 0.75
[Morbidity and mortality in systemic rheumatoid diseases: how did they change?]. Z Rheumatol (2011) 0.75
[Life and suffering 5,000 years ago. Paleopathologic findings in the "man from the ice"]. MMW Fortschr Med (1999) 0.75
[Epidemiology of accidents in childhood]. Monatsschr Kinderheilkd (1984) 0.75
[Basic treatment of early rheumatoid arthritis. Abstaining from rheumatological care and preferring alternative medicine increase the risk of undertreatment]. Z Rheumatol (2007) 0.75
[Presentation of the Center of Competence in Berlin]. Z Rheumatol (2002) 0.75
Action of calcitonin gene-related peptide at the calcitonin receptor of the T47D cell line. Horm Metab Res (1987) 0.75
Childhood poisoning in a paediatric hospital: the Luebeck experience. Hum Toxicol (1983) 0.75
[The importance of patient perspective in drug surveillance systems]. Z Rheumatol (2010) 0.75
[Primary human demodicosis. A disease sui generis]. Hautarzt (2015) 0.75
[Goals and methods of clinical studies]. Z Rheumatol (2000) 0.75
[Preface]. Z Rheumatol (2002) 0.75
Long-term exposure to SMS 201-995 inhibits proliferation and calcitonin release in neoplastic C-cells. Horm Metab Res (1993) 0.75
Regulation of calcitonin secretion in vitro. Horm Metab Res (1993) 0.75
Evaluation of sensitive PDN-21 (katacalcin) determination as tumor marker in medullary thyroid carcinoma. J Endocrinol Invest (1992) 0.75
["Don't smoke"--a confirmed factor in the primary prevention of rheumatoid arthritis]. Z Rheumatol (2006) 0.75
A shortened docetaxel desensitization protocol for use in special cases. J Eur Acad Dermatol Venereol (2011) 0.75
Regulation of calcitonin secretion and calcitonin gene expression. Recent Results Cancer Res (1992) 0.75
[The role of somatostatin on the cellular level]. Med Klin (Munich) (1993) 0.75
An open distributed medical image and signal data server network with World Wide Web front-end. Stud Health Technol Inform (1997) 0.75
[Results of early rehabilitation using various knee prosthesis models]. Rehabilitation (Stuttg) (1996) 0.75